Comparison of Type 2 Diabetes Pharmacotherapy Regimens
Public ClinicalTrials.gov record NCT05073692. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Comparison of Type 2 Diabetes Pharmacotherapy Regimens Using Targeted Learning
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is designed to help patients with type 2 diabetes and their clinicians: (a) identify which glucose lowering medications have the most favorable effects on heart health and other patient-important outcomes, (b) inform the timing of medication initiation, and (c) identify whether medication benefits apply equally to all adults with type 2 diabetes, or may be different based on age, sex, race/ethnicity, baseline heart health status, baseline renal function, or other factors.
Study identification
- NCT ID
- NCT05073692
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 241,981 participants
Conditions and interventions
Conditions
Interventions
- SU Drug
- DPP4 Drug
- SGLT2i Drug
- GLP-1RA Drug
- SGLT2i or GLP-1RA Drug
- Linagliptin (DPP4) Drug
- Exenatide (GLP-1RA) Drug
- Liraglutide (GLP-1RA) Drug
- Empagliflozin (SGLT2i) Drug
- Glimepiride (SU) Drug
- Glipizide (SU) Drug
- Glimepiride (SU) or Glipizide (SU) Drug
- SU or DPP4 (excluding saxagliptin and alogliptin) Drug
- Exenatide (GLP-1RA) or Liraglutide (GLP-1RA) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2021
- Primary completion
- Dec 30, 2024
- Completion
- Mar 11, 2025
- Last update posted
- Nov 20, 2025
2021 – 2025
United States locations
- U.S. sites
- 6
- U.S. states
- 5
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Kaiser Permanente Southern California | Pasadena | California | 91101 | — |
| Romain S. Neugebauer | Pleasanton | California | 94588 | — |
| Kaiser Permanente Hawaii | Honolulu | Hawaii | 96817 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| HealthPartners Institute | Bloomington | Minnesota | 55425 | — |
| Geisinger | Danville | Pennsylvania | 17821 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05073692, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 20, 2025 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05073692 live on ClinicalTrials.gov.